ARTICLE | Clinical News
Apellis pauses Phase III trials after single lot of APL-2 causes inflammation
October 19, 2018 6:34 PM UTC
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) voluntarily paused dosing in Phase III trials of intravitreal APL-2 to treat geographic atrophy due to eight reported cases of non-infectious inflammation in patients treated from a single manufacturing lot of the product.
The company said it believes the inflammation is isolated to the single lot based on a preliminary toxicity analysis, and if confirmed by a series of non-human studies, Apellis will resume dosing in the Phase III program by year end...
BCIQ Company Profiles
BCIQ Target Profiles